The funniest part about your argument is all it does is show how valuable Elite's tech is to companies that do not have patented abuse resistant technology.
You keep talking about PH3 trials but Elite is not pursuing PH3 right now which would be for a 24 oxy product
They are working on ANDAs and 505B2 NDAs
So the questions remain
What do you think the ANDAs are?
What do you think the NDAs are?
What do you think they are trialing with the 505B2 trials?
What do you think the 505B2 products started 2 years ago with Actavis/Mikah are?
And since there will not be an announcement or public statement describing the studies as noted by the company, why would we find them on the government website?
Market Data 
Markets 
